TuisMEHCQ • OTCMKTS
add
23andMe Holding Co.
Vorige sluiting
$1,17
Dagwisseling
$1,07 - $1,18
Jaarwisseling
$0,48 - $12,76
Markkapitalisasie
30,85 m USD
Gemiddelde volume
8,09 m
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
OTCMKTS
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
(USD) | Des. 2024info | J/J-verandering |
---|---|---|
Inkomste | 60,26 m | 34,67% |
Bedryfskoste | 65,06 m | -22,18% |
Netto inkomste | -53,04 m | 80,92% |
Netto winsgrens | -88,01 | 85,83% |
Wins per aandeel | — | — |
EBITDA | -21,80 m | 62,70% |
Effektiewe belastingkoers | — | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
(USD) | Des. 2024info | J/J-verandering |
---|---|---|
Kontant en korttermynbeleggings | 79,35 m | -67,27% |
Totale bates | 277,42 m | -54,39% |
Totale aanspreeklikheid | 214,70 m | -7,06% |
Totale ekwiteit | 62,72 m | — |
Uitstaande aandele | 26,83 m | — |
Prys om te bespreek | 0,50 | — |
Opbrengs op bates | -21,15% | — |
Opbrengs op kapitaal | -42,49% | — |
Kontantvloei
Netto kontantverandering
(USD) | Des. 2024info | J/J-verandering |
---|---|---|
Netto inkomste | -53,04 m | 80,92% |
Kontant van bedrywe | -44,65 m | -270,23% |
Kontant van beleggings | 887,00 k | 144,09% |
Kontant van finansiering | -19,00 k | -118,10% |
Netto kontantverandering | -43,79 m | -213,47% |
Beskikbare kontantvloei | -20,18 m | -469,10% |
Meer oor
23andMe Holding Co. is an American personal genomics and biotechnology company based in South San Francisco, California. It is best known for providing a direct-to-consumer genetic testing service in which customers provide a saliva sample that is laboratory analysed, using single nucleotide polymorphism genotyping, to generate reports relating to the customer's ancestry and genetic predispositions to health-related topics. The company's name is derived from the 23 pairs of chromosomes in a diploid human cell.
Founded in 2006, 23andMe soon became the first company to begin offering autosomal DNA testing for ancestry, which all other major companies now use. Its saliva-based direct-to-consumer genetic testing business was named "Invention of the Year" by Time in 2008.
The company had a previously fraught relationship with the United States Food and Drug Administration due to its genetic health tests; as of October 2015, DNA tests ordered in the US include a revised health component, per FDA approval. 23andMe has been selling a product with both ancestry and health-related components in Canada since October 2014, and in the UK since December 2014. Wikipedia
Gestig
Apr. 2006
Webwerf
Werknemers
571